Andrea Piolatto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrea Piolatto has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Filomena Longo
Dipartimento di Medicina Specialistica—Day Hospital della Talassemia e delle Emoglobinopatie, Azienda Ospedaliero-Universitaria Arcispedale “S. Anna”, 44124 Cona, FE, Italy
4 shared publications - Antonio Piga
Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
3 shared publications - Giovanni Battista Ferrero
SSD Microcitemie e Malattie Rare Ematologiche Ospedale San Luigi Gonzaga, Orbassano Torino Italy
3 shared publications - Immacolata Tartaglione
Dipartimento della Donna, del bambino e della chirurgia generale e specialistica, Università della Campania "Luigi Vanvitelli", Campania, Italy.
1 shared publication - Irene Motta
Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza 2023–2027 University of Milan Milan Italy
1 shared publication - Nicolò Tesio
Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland
1 shared publication
Latest Publications
- Open Access
- 29 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (7) , 2584
Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
Luspatercept has recently been approved for the treatment of beta-thalassemia and its use in clinical practice has been increasing. As it is the first erythroid maturation drug available for this diagnosis, the expertise about its use is still limited. To address this point, and to promote awareness and guide the clinical use of luspatercept in beta-thalassemia, this paper was developed as a consensus by experts from the Italian Society of Thalassemia and Hemoglobinopathies (SITE). After a brief presentation of the core features of luspatercept, a comprehensive set of questions is addressed, covering relevant aspects for the practical management of this new therapeutic option.
- 29 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (7) , 2584
Open AccessTreating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
Luspatercept has recently been approved for the treatment of beta-thalassemia and its use in clinical practice has been increasing. As it is the first erythroid maturation drug available for this diagnosis, the expertise about its use is still limited. To address this point, and to promote awareness and guide the clinical use of luspatercept in beta-thalassemia, this paper was developed as a consensus by experts from the Italian Society of Thalassemia and Hemoglobinopathies (SITE). After a brief presentation of the core features of luspatercept, a comprehensive set of questions is addressed, covering relevant aspects for the practical management of this new therapeutic option.
- Open Access
- 10 November 2021
- Published by Taylor & Francis in Future Rare Diseases
- Vol. 1 (4)
Luspatercept for the Treatment of β-Thalassemia: from Preclinical Research to Clinical Practice and Beyond
β-thalassemia is an inherited disease causing an impaired hemoglobin production, eventually leading to a severe chronic anemia. Resolutive treatments are still limited to a small number of patients... Lay abstract β-thalassemia is an inherited disease causing a severe reduction of hemoglobin, the protein of red blood cells (RBCs) responsible of delivering oxygen to the body. This means a severe ...
- 10 November 2021
- Published by Taylor & Francis in Future Rare Diseases
- Vol. 1 (4)
Open AccessLuspatercept for the Treatment of β-Thalassemia: from Preclinical Research to Clinical Practice and Beyond
β-thalassemia is an inherited disease causing an impaired hemoglobin production, eventually leading to a severe chronic anemia. Resolutive treatments are still limited to a small number of patients... Lay abstract β-thalassemia is an inherited disease causing a severe reduction of hemoglobin, the protein of red blood cells (RBCs) responsible of delivering oxygen to the body. This means a severe ...
- Open Access
- 5 July 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 7229
Ineffective Erythropoiesis in β-Thalassaemia: Key Steps and Therapeutic Options by Drugs
β-thalassaemia is a rare genetic condition caused by mutations in the β-globin gene that result in severe iron-loading anaemia, maintained by a detrimental state of ineffective erythropoiesis (IE). The role of multiple mechanisms involved in the pathophysiology of the disease has been recently unravelled. The unbalanced production of α-globin is a major source of oxidative stress and membrane damage in red blood cells (RBC). In addition, IE is tightly linked to iron metabolism dysregulation, and the relevance of new players of this pathway, i.e., hepcidin, erythroferrone, matriptase-2, among others, has emerged. Advances have been made in understanding the balance between proliferation and maturation of erythroid precursors and the role of specific factors in this process, such as members of the TGF-β superfamily, and their downstream effectors, or the transcription factor GATA1. The increasing understanding of IE allowed for the development of a broad set of potential therapeutic options beyond the current standard of care. Many candidates of disease-modifying drugs are currently under clinical investigation, targeting the regulation of iron metabolism, the production of foetal haemoglobin, the maturation process, or the energetic balance and membrane stability of RBC. Overall, they provide tools and evidence for multiple and synergistic approaches that are effectively moving clinical research in β-thalassaemia from bench to bedside.
- 5 July 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 7229
Open AccessIneffective Erythropoiesis in β-Thalassaemia: Key Steps and Therapeutic Options by Drugs
β-thalassaemia is a rare genetic condition caused by mutations in the β-globin gene that result in severe iron-loading anaemia, maintained by a detrimental state of ineffective erythropoiesis (IE). The role of multiple mechanisms involved in the pathophysiology of the disease has been recently unravelled. The unbalanced production of α-globin is a major source of oxidative stress and membrane damage in red blood cells (RBC). In addition, IE is tightly linked to iron metabolism dysregulation, and the relevance of new players of this pathway, i.e., hepcidin, erythroferrone, matriptase-2, among others, has emerged. Advances have been made in understanding the balance between proliferation and maturation of erythroid precursors and the role of specific factors in this process, such as members of the TGF-β superfamily, and their downstream effectors, or the transcription factor GATA1. The increasing understanding of IE allowed for the development of a broad set of potential therapeutic options beyond the current standard of care. Many candidates of disease-modifying drugs are currently under clinical investigation, targeting the regulation of iron metabolism, the production of foetal haemoglobin, the maturation process, or the energetic balance and membrane stability of RBC. Overall, they provide tools and evidence for multiple and synergistic approaches that are effectively moving clinical research in β-thalassaemia from bench to bedside.
- Open Access
- 15 June 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-12
Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring
Deferasirox (DFX) is the newest among three different chelators available to treat iron overload in iron-loading anaemias, firstly released as Dispersible Tablets (DT) and more recently replaced by Film-Coated Tablets (FCT). In this retrospective observational study, pharmacokinetics, pharmacodynamics, and safety features of DFX treatment were analyzed in 74 patients that took both formulations subsequently under clinical practice conditions. Bioavailability of DFX FCT compared to DT resulted higher than expected [Cmax: 99.5 (FCT) and 69.7 (DT) μMol/L; AUC: 1278 (FCT) and 846 (DT), P < 0.0001]. DFX FCT was also superior in scalability among doses. After one year of treatment for each formulation, no differences were observed between the treatments in the overall iron overload levels; however, DFX FCT but not DT showed a significant dose–response correlation [Spearman r (dose-serum ferritin variation): − 0.54, P < 0.0001]. Despite being administered at different dosages, the long-term safety profile was not different between formulations: a significant increase in renal impairment risk was observed for both treatments and it was reversible under strict monitoring (P < 0.002). Altogether, these data constitute a comprehensive comparison of DFX formulations in thalassaemia and other iron-loading anaemias, confirming the effectiveness and safety characteristics of DFX and its applicability for treatment tailoring.
- 15 June 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-12
Open AccessPharmacological and clinical evaluation of deferasirox formulations for treatment tailoring
Deferasirox (DFX) is the newest among three different chelators available to treat iron overload in iron-loading anaemias, firstly released as Dispersible Tablets (DT) and more recently replaced by Film-Coated Tablets (FCT). In this retrospective observational study, pharmacokinetics, pharmacodynamics, and safety features of DFX treatment were analyzed in 74 patients that took both formulations subsequently under clinical practice conditions. Bioavailability of DFX FCT compared to DT resulted higher than expected [Cmax: 99.5 (FCT) and 69.7 (DT) μMol/L; AUC: 1278 (FCT) and 846 (DT), P < 0.0001]. DFX FCT was also superior in scalability among doses. After one year of treatment for each formulation, no differences were observed between the treatments in the overall iron overload levels; however, DFX FCT but not DT showed a significant dose–response correlation [Spearman r (dose-serum ferritin variation): − 0.54, P < 0.0001]. Despite being administered at different dosages, the long-term safety profile was not different between formulations: a significant increase in renal impairment risk was observed for both treatments and it was reversible under strict monitoring (P < 0.002). Altogether, these data constitute a comprehensive comparison of DFX formulations in thalassaemia and other iron-loading anaemias, confirming the effectiveness and safety characteristics of DFX and its applicability for treatment tailoring.